MESSAGE FROM THE DIRECTOR
Stan Gerson, MD
Director, Case CCC
Dear Cancer Center Members:
It's hard to believe that come next Thursday and Friday, July 10-11, will host another Cancer Center Scientific Retreat. We have a spectacular agenda, with something (many things), for all of us to learn from, appreciate, and use as the basis of new collaborations and discussion.
In our busy schedules, taking a bit of time to collect, think and conjecture is what makes this work exhilarating. For those of you who have not looked over the schedule in detail, let me highlight a few things.
First, I would like to thank Mohamed Abazeed, Goutham Narla, Johnie Rose, Nima Sharifi, John Wang, and Scott Welford for organizing and developing the program for the retreat. It has been many hours coordinating topics, schedules, and speakers.
Dr. Kevin Shannon, the Auerback Distinguished Professor in Molecular Oncology at the UCSF Cancer Center, will discuss, at 5:10 on Thursday in the Wolstein Research Building, his work on Ras and the huge new NCI project in understanding Ras to the point of identifying drugs to interfere with its oncogenic properties.
Also on Thursday, new members will be identified, and many will have a poster on display during the reception following Kevin's talk.
On Friday, July 11, the retreat will move to Corporate College East on Richmond Road starting at 7:45 am, with my overview of the Center at 8:20.
We then will have a series of talks for members clustered into areas of broad interest, with recent data and new approaches, with most presentations being given by recent institutional and Center recruits, and members with interesting "hot" topics. I will not highlight individuals except to say that we have not recently had presentations by any of them to the entire membership. We will leave plenty of time for discussion after each session.
In the middle of the day, we will have program breakouts to discuss their strategic initiatives, and importantly, to receive member input on how to spend our discretionary support in pilot projects in the coming year. Your input can be heard at that time, and if not, you may lose the opportunity to have your perspective heard.
We will also have tables for each Core Facility that can be visited during the breaks to ask for guidance in your experimental needs.
Finally, we have a large number of trainees from your labs who have agreed to participate in the poster discussion, and we will have awards at the end of the reception, which runs from 4:35-7:00 pm.
It will be an exciting and productive retreat. I look forward to talking to you there! Please register today!
CASE CCC IN THE NEWS
Cancer Care Under the Affordable Care Act
ASCO Post- June 25, 2014
According to health policy expert, Siran M. Koroukian, PhD,Associate Professor in the Department of Epidemiology and Biostatistics at Case Western Reserve University, Cleveland and member of the Case Comprehensive Cancer Center, most studies that compare cancer outcomes between Medicaid patients and the uninsured rely on data that reflect insurance status at a given point in time, such as time of diagnosis, without accounting for the patient’s history of enrollment in relation to the diagnosis of cancer...According to Johnie Rose, MD, PhD, Assistant Professor and Preventive Medicine Residency Program Director at Case Western Reserve University and member of the Case Comprehensive Cancer Center, a significant benefit of the Affordable Care Act is improved access to numerous evidence-based preventive services.
New Option for Preserving Fertility in Women Being Treated With Chemotherapy for Early-Stage Breast Cancer
ASCO Post- June 25, 2014
One of the most reported studies emanating from the 2014 ASCO Annual Meeting involves the use of the luteinizing hormone–releasing hormone (LHRH) agonist goserelin (Zoladex) to reduce the risk of ovarian failure among women being treated with chemotherapy for early-stage breast cancer, and to increase the likelihood of a successful pregnancy afterward...In an interview with The ASCO Post, the study’s lead author, Halle Moore, MD, said that she welcomed the media coverage because "the more the public is aware of fertility preservation options for patients receiving chemotherapy, the more likely it is that those patients will ask their doctors about [such measures]." Dr. Moore is a Staff Physician and Chair of the Survivorship Program at the Cleveland Clinic. She is also a member of the Case Comprehensive Cancer Center.
FDA Panel Puts Brakes on Anti-PARP Drug
MedPage Today - June 25, 2014
Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against accelerated approval..."There were some significant problems with the data that were being submitted," ODAC chair Mikkael Sekeres, MD, of the Cleveland Clinic and Case Comprehensive Cancer Center, told MedPage Today. "A couple of factors swayed my decision [to vote against immediate approval]...
3D mammogram: Fewer Call-backs and Better Breast Cancer Detection When Used, Study Shows
Wall Street Journal - June 24, 2014
Breast-cancer screening with three-dimensional imaging finds more invasive cancers and yields fewer false alarms than standard digital mammograms alone, according to a new study in the "Journal of the American Medical Association"...in the JAMA study, researchers at 13 sites compared records of 281,187 women who had digital mammograms alone with 173,663 who had the 2-D and 3-D versions. Adding the 3-D imaging decreased the rate of recalls by about 10%—from 107 per 1,000 exams to 91 per 1,000. At the same time, 3-D mammograms detected 41% more invasive cancers, finding 4.1 per 1,000 exams, compared with 2.9 per 1,000 for digital mammography alone. "Those are the harmful cancers that we want to find, and it saves women the anxiety and cost of having additional exams for what turn out to be a false alarm,"said Donna Plecha, a study co-author, director of Breast Imaging at University Hospitals Case Medical Center in Cleveland, and member of the Case Comprehensive Cancer Center.
RESEARCH HIGHLIGHTS/MEMBER NEWS
Synthetic Triterpenoids Show Promise in Preventing Colitis-Associated Colon Cancer
Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for suppressing colon cancer associated with colitis. These findings, published in an early June edition of the "Journal of Clinical Investigation," offer hope that physicians ultimately will be able to reduce dramatically the number of sufferers of this inflammatory bowel disease (IBD) who go on to develop colon cancer.
"Patients with inflammatory bowel disease have a 10-fold greater risk of colon cancer, placing it among the top three high-risk conditions for colorectal cancer," said senior author and hematologist/oncologist John Letterio, MD, professor of pediatrics, Case Western Reserve University School of Medicine, director of the Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital, and member of the Case Comprehensive Cancer Center. "Common epithelial cancers develop over a period of years, even decades, in populations at high risk due to genetic predisposition, so chemoprevention strategies could delay, or even halt, onset of clinically evident colon cancer."
Colleague and fellow Cancer Center member Sanford Markowitz, MD, PhD, Ingalls Professor of Cancer Genetics at Case Western Reserve School of Medicine, served an important role in this investigation because of his expertise as the innovator who first characterized 15-PGDH, an important tumor suppressor and natural anti-inflammatory.
Drs. Barnholtz-Sloan and Peereboom to Co-Chair Neuro-Oncology Initiative for Ohio Clinical Trials Collaborative
The Ohio Clinical Trials Collaborative (OCTC) has appointed Jill Barnholtz-Sloan, PhD, as Chair of its Neuro-Oncology Working Group. Barnholtz-Sloan is an Associate Professor at Case Western Reserve University School of Medicine, Associate Director for Clinical Informatics, Institute for Computational Biology, and a member of the Case Comprehensive Cancer Center.
The adult component of this working group will be co-chaired by David Peereboom, MD, Professor of Medicine at Cleveland Clinic Lerner College of Medicine, Director, Clinical Research at The Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, and member of the Case Comprehensive Cancer Center, and the pediatric component of this working group will be co-chaired by Jonathan Finlay, MD, Professor and Director of Pediatric Neuro-Oncology at Nationwide Children's Hospital.
The OCTC provides centralized access to Ohio's premier medical centers for clinical trial development. The pharmaceutical industry faces a challenging and expensive process for conduct of clinical trials. The OCTC streamlines the contracting, budgeting, approval of human subject use and patient recruitment/enrollment processes so medical discoveries can move to market faster.
NCRM: Demonstration Projects in OH-Alive 2014
The National Center for Regenerative Medicine (NCRM) is accepting proposals to fund Demonstration Projects for the OH-Alive Innovator Platform: A Process and Manufacturing platform for Cell Therapy. The purpose of this RFP is to assist in the development of novel cell therapeutics and diagnostic platforms that will lead to both commercializable products and clinical interventions.
LOI Deadline: July 1
2014 Grant Writers Coaching Group for NIH Awards
Faculty members who are working on a National Institutes of Health (NIH) Career Development K or R grant proposals and need additional support are invited to apply for the 2014 Grant Writers Coaching Group for NIH Awards, being held September 5 in Vancouver. This one-day workshop (followed by three months of optional online sessions and support) is designed to provide practical knowledge, skills, and one-on-one guidance to submit a competitive proposal.
Deadline: July 10
Mesothelioma Applied Research Foundation
Mesothelioma Applied Research Foundation is accepting applications for its research grant program. Eligible projects may relate to benchwork, translational or clinical research that is not presently funded and may be conducted through any not-for-profit academic, medical or research institution. All levels and degrees of scientists are encouraged to apply.
Deadline: August 8
MARK YOUR CALENDARS
NCRM Cancer Stem Cell Conference
The first CWRU: National Center for Regenerative Medicine Cancer Stem Cell Conference will be held in Cleveland, August 17-20, 2014. This conference is guaranteed to have incredible research from a variety of backgrounds in the Cancer Stem Cell field, and will feature keynote speakers from over 25 different institutions from around the world.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
Damon Runyon-Rachleff Innovation Award
DoD Prostate Cancer Research Program Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award
NIH BULLETIN – Notices and Funding Opportunities
Outstanding Investigator Award (R35)(PAR-14-267)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.